COMPUGROUP MEDICAL SE & CO K (COP.DE) Fundamental Analysis & Valuation
FRA:COP • DE000A288904
Current stock price
22.66 EUR
+0.24 (+1.07%)
Last:
This COP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. COP.DE Profitability Analysis
1.1 Basic Checks
- COP had positive earnings in the past year.
- COP had a positive operating cash flow in the past year.
- In the past 5 years COP has always been profitable.
- COP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- COP has a Return On Assets (1.34%) which is comparable to the rest of the industry.
- COP's Return On Equity of 4.15% is in line compared to the rest of the industry. COP outperforms 50.00% of its industry peers.
- COP has a worse Return On Invested Capital (3.53%) than 60.00% of its industry peers.
- COP had an Average Return On Invested Capital over the past 3 years of 4.07%. This is below the industry average of 7.44%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROIC | 3.53% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
1.3 Margins
- COP has a Profit Margin (2.34%) which is in line with its industry peers.
- COP's Profit Margin has declined in the last couple of years.
- The Operating Margin of COP (8.13%) is comparable to the rest of the industry.
- In the last couple of years the Operating Margin of COP has declined.
- COP has a Gross Margin of 83.85%. This is in the better half of the industry: COP outperforms 70.00% of its industry peers.
- COP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% |
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
2. COP.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), COP is destroying value.
- The number of shares outstanding for COP has been reduced compared to 1 year ago.
- The number of shares outstanding for COP has been increased compared to 5 years ago.
- The debt/assets ratio for COP is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.79, we must say that COP is in the distress zone and has some risk of bankruptcy.
- COP has a Altman-Z score (1.79) which is in line with its industry peers.
- The Debt to FCF ratio of COP is 9.74, which is on the high side as it means it would take COP, 9.74 years of fcf income to pay off all of its debts.
- COP has a Debt to FCF ratio (9.74) which is in line with its industry peers.
- A Debt/Equity ratio of 1.22 is on the high side and indicates that COP has dependencies on debt financing.
- COP has a Debt to Equity ratio of 1.22. This is amonst the worse of the industry: COP underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Altman-Z | 1.79 |
ROIC/WACC0.67
WACC5.27%
2.3 Liquidity
- A Current Ratio of 1.12 indicates that COP should not have too much problems paying its short term obligations.
- The Current ratio of COP (1.12) is worse than 60.00% of its industry peers.
- A Quick Ratio of 1.09 indicates that COP should not have too much problems paying its short term obligations.
- COP has a Quick ratio of 1.09. This is in the lower half of the industry: COP underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 |
3. COP.DE Growth Analysis
3.1 Past
- COP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.71%.
- COP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.58% yearly.
- Looking at the last year, COP shows a decrease in Revenue. The Revenue has decreased by -2.19% in the last year.
- The Revenue has been growing by 9.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
3.2 Future
- COP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.19% yearly.
- The Revenue is expected to grow by 0.36% on average over the next years.
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. COP.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 43.58, which means the current valuation is very expensive for COP.
- COP's Price/Earnings ratio is in line with the industry average.
- COP is valuated expensively when we compare the Price/Earnings ratio to 27.35, which is the current average of the S&P500 Index.
- COP is valuated correctly with a Price/Forward Earnings ratio of 12.88.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of COP indicates a somewhat cheap valuation: COP is cheaper than 70.00% of the companies listed in the same industry.
- COP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.23.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, COP is valued a bit cheaper than the industry average as 70.00% of the companies are valued more expensively.
- 80.00% of the companies in the same industry are more expensive than COP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.34 | ||
| EV/EBITDA | 9.24 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COP does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)31.03
PEG (5Y)N/A
EPS Next 2Y4.91%
EPS Next 3Y9.19%
5. COP.DE Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.22%, COP is not a good candidate for dividend investing.
- COP's Dividend Yield is comparable with the industry average which is at 2.36.
- Compared to an average S&P500 Dividend Yield of 1.82, COP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
5.2 History
- On average, the dividend of COP grows each year by 14.75%, which is quite nice.
Dividend Growth(5Y)14.75%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
- COP pays out 191.63% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of COP is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP191.63%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
COP.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:COP (6/24/2025, 7:00:00 PM)
22.66
+0.24 (+1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-31 2025-07-31
Inst Owners13.38%
Inst Owner ChangeN/A
Ins Owners53.51%
Ins Owner ChangeN/A
Market Cap1.22B
Revenue(TTM)1.16B
Net Income(TTM)27.00M
Analysts56.67
Price Target21.32 (-5.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
Yearly Dividend1
Dividend Growth(5Y)14.75%
DP191.63%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 | ||
| P/S | 1.05 | ||
| P/FCF | 14.34 | ||
| P/OCF | 8.46 | ||
| P/B | 1.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.24 |
EPS(TTM)0.52
EY2.29%
EPS(NY)1.76
Fwd EY7.76%
FCF(TTM)1.58
FCFY6.97%
OCF(TTM)2.68
OCFY11.82%
SpS21.51
BVpS12.12
TBVpS-12.86
PEG (NY)31.03
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROCE | 5.85% | ||
| ROIC | 3.53% | ||
| ROICexc | 3.83% | ||
| ROICexgc | 41.76% | ||
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% | ||
| FCFM | 7.35% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
ROICexc(3y)4.31%
ROICexc(5y)4.74%
ROICexgc(3y)36.56%
ROICexgc(5y)51.39%
ROCE(3y)6.74%
ROCE(5y)7.38%
ROICexgc growth 3Y-23.91%
ROICexgc growth 5Y-9.04%
ROICexc growth 3Y-4.3%
ROICexc growth 5Y-14.26%
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Debt/EBITDA | 3.86 | ||
| Cap/Depr | 52.61% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 69.81% | ||
| Profit Quality | 314.42% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | 1.79 |
F-Score6
WACC5.27%
ROIC/WACC0.67
Cap/Depr(3y)60.99%
Cap/Depr(5y)64.22%
Cap/Sales(3y)5.98%
Cap/Sales(5y)6.31%
Profit Quality(3y)175.79%
Profit Quality(5y)158.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
EBIT growth 1Y-18.88%
EBIT growth 3Y1.31%
EBIT growth 5Y-2.11%
EBIT Next Year77.58%
EBIT Next 3Y24.98%
EBIT Next 5Y17.79%
FCF growth 1Y3.01%
FCF growth 3Y-11.08%
FCF growth 5Y-0.24%
OCF growth 1Y-8.49%
OCF growth 3Y-7.96%
OCF growth 5Y3.13%
COMPUGROUP MEDICAL SE & CO K / COP.DE Fundamental Analysis FAQ
What is the ChartMill fundamental rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to COP.DE.
Can you provide the valuation status for COMPUGROUP MEDICAL SE & CO K?
ChartMill assigns a valuation rating of 3 / 10 to COMPUGROUP MEDICAL SE & CO K (COP.DE). This can be considered as Overvalued.
Can you provide the profitability details for COMPUGROUP MEDICAL SE & CO K?
COMPUGROUP MEDICAL SE & CO K (COP.DE) has a profitability rating of 4 / 10.
Can you provide the financial health for COP stock?
The financial health rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10.
How sustainable is the dividend of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
The dividend rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10 and the dividend payout ratio is 191.63%.